{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:58:04Z","timestamp":1792400284929,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-026-03497-4","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:33:26Z","timestamp":1770032006000},"page":"1308-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-8264","authenticated-orcid":false,"given":"Daniel","family":"Lachant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amresh","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Albert","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Elwing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"38","key":"3497_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"3497_CR2","unstructured":"Orenitram (package insert). 2023."},{"issue":"6","key":"3497_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","volume":"201","author":"RJ White","year":"2020","unstructured":"White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2020;201(6):707\u201317.","journal-title":"Am J Respir Crit Care Med"},{"key":"3497_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106744","volume":"193","author":"A Khan","year":"2022","unstructured":"Khan A, White RJ, Meyer G, Pulido Zamudio TR, Jerjes-Sanchez C, Johnson D, et al. Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension. Respir Med. 2022;193:106744.","journal-title":"Respir Med"},{"issue":"11","key":"3497_CR5","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.healun.2022.08.006","volume":"41","author":"RL Benza","year":"2022","unstructured":"Benza RL, Gomberg-Maitland M, Farber HW, Vizza CD, Broderick M, Holdstock L, et al. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV. J Heart Lung Transplant. 2022;41(11):1572\u201380.","journal-title":"J Heart Lung Transplant"},{"key":"3497_CR6","doi-asserted-by":"crossref","unstructured":"Brewer J, Anguiano R, Awdish R, Coons J, Kimber A, Morrison A, et al., editors. (2021) An Expert Panel Delphi Consensus Statement on Appropriate Patient Selection and Management of Adverse Events in Patients Receiving Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension. ATS International Conference; Virtual.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A3618"},{"key":"3497_CR7","doi-asserted-by":"crossref","unstructured":"Wu B, Morland K, Classi P, Sketch M, Nelsen A, Goyal R, et al., editors. (2021) Economic Burden of Patients with Pulmonary Arterial Hypertension Prior to Initiation of Treprostinil: A Retrospective Analysis of US Claims Data. American Thoracic Society; Virtual.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1571"},{"issue":"3","key":"3497_CR8","first-page":"229","volume":"7","author":"BB Dean","year":"2020","unstructured":"Dean BB, Saundankar V, Stafkey-Mailey D, Anguiano RH, Nelsen AC, Gordon K, et al. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs. 2020;7(3):229\u201339.","journal-title":"Drugs"},{"key":"3497_CR9","doi-asserted-by":"crossref","unstructured":"Classi P, editor Outcomes and costs associated with oral treprostinil and selexipag one year into treatment: a U.S. claims database analysis in patients with pulmonary arterial hypertension. Chest; 2021.","DOI":"10.1016\/j.chest.2021.07.1980"},{"issue":"6","key":"3497_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383\u201390.","journal-title":"Chest"},{"issue":"3","key":"3497_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1378\/chest.12-2875","volume":"144","author":"VF Tapson","year":"2013","unstructured":"Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952\u20138.","journal-title":"Chest"},{"issue":"12","key":"3497_CR12","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1164\/rccm.201602-0274LE","volume":"193","author":"RJ White","year":"2016","unstructured":"White RJ, Rao Y. Novel analysis of the oral treprostinil combination therapy trial data. Am J Respir Crit Care Med. 2016;193(12):1434\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3497_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"issue":"1","key":"3497_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","volume":"159","author":"RL Benza","year":"2021","unstructured":"Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337\u201346.","journal-title":"Chest"},{"issue":"1","key":"3497_CR15","doi-asserted-by":"publisher","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","volume":"60","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Gr\u00fcnig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311.","journal-title":"Eur Respir J"},{"issue":"1","key":"3497_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1086\/690109","volume":"7","author":"FF Rahaghi","year":"2017","unstructured":"Rahaghi FF, Feldman JP, Allen RP, Tapson V, Safdar Z, Balasubramanian VP, et al. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulm Circ. 2017;7(1):167\u201374.","journal-title":"Pulm Circ"},{"key":"3497_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107734","volume":"231","author":"J Brewer","year":"2024","unstructured":"Brewer J, Wilson M, Coons JC, Schmit A, Whittenhall ME, Kimber A, et al. Practical management of oral treprostinil in patients with pulmonary arterial hypertension: lessons from ADAPT, EXPEDITE, and expert consensus. Respir Med. 2024;231:107734.","journal-title":"Respir Med"},{"issue":"26","key":"3497_CR18","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"3497_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.chest.2022.08.2231","volume":"163","author":"LS Howard","year":"2023","unstructured":"Howard LS, Rosenkranz S, Frantz RP, Hemnes AR, Pfister T, Hsu Schmitz SF, et al. Assessing daily life physical activity by actigraphy in pulmonary arterial hypertension: insights from the randomized controlled study with selexipag (TRACE). Chest. 2023;163(2):407\u201318.","journal-title":"Chest"},{"issue":"3","key":"3497_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12255","volume":"13","author":"JF Kingrey","year":"2023","unstructured":"Kingrey JF, Miller CE, Franco V, Smith JS, Zolty R, Oudiz RJ, et al. Implementing the EXPEDITE parenteral induction protocol: rapid parenteral treprostinil titration and transition to oral treprostinil. Pulm Circ. 2023;13(3):e12255.","journal-title":"Pulm Circ"},{"key":"3497_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107374","volume":"218","author":"CE Miller","year":"2023","unstructured":"Miller CE, Franco V, Smith JS, Balasubramanian V, Kingrey J, Zolty R, et al. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respir Med. 2023;218:107374.","journal-title":"Respir Med"},{"key":"3497_CR22","doi-asserted-by":"crossref","unstructured":"White RJ, Gr\u00fcnig E, Jerjes-Sanchez D C, Bohns Meyer GM, Pulido T, Sepulveda P, et al. (2019) Dose-response relationship of oral treprostinil for secondary endpoints in the FREEDOM-EV study. PA5462.","DOI":"10.1183\/13993003.congress-2019.PA5462"},{"issue":"2","key":"3497_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.healun.2016.06.019","volume":"36","author":"MM Chakinala","year":"2017","unstructured":"Chakinala MM, Feldman JP, Rischard F, Mathier M, Broderick M, Leedom N, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant. 2017;36(2):193\u2013201.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"3497_CR24","doi-asserted-by":"publisher","first-page":"A2363","DOI":"10.1016\/j.chest.2022.08.1946","volume":"162","author":"JM Elwing","year":"2022","unstructured":"Elwing JM, F Rahaghi F, Hage A, Dv Vizza C, Gr\u00fcnig E, K Wang K, et al. Oral treprostinil as part of a triple-therapy regimen for pulmonary arterial hypertenion: analysis from the FREEDOM-EV open-label extension. Chest. 2022;162(4):A2363\u20134.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03497-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:28:59Z","timestamp":1773822539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03497-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3497"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03497-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D. Lachant has received consulting fees from Merck and Jansen. The University of Rochester receives research funds from United Therapeutics. A. Raina is part of the governance of the ABIM cardiovascular disease board. M. Krishnan is on the speakers bureau for Liquidia and is on the scientific advisory board\/consults for United Therapeutics, Johnson & Johnson, and Liquidia. N. Sood has received consulting fees from United Therapeutics, Gossamer, Merck, and Boehringer Ingelheim, as well as honoraria from Bayer for lectures, presentations, speakers bureaus, manuscript writing or educational events. The University of California-Davis receives research funds from United Therapeutics, Gossamer, Merck, Pulmovant, and Pfizer. V. Balasubramanian is on the speakers bureau for United Therapeutics, Merck, Liquidia, and Boehringer Ingelheim; conduct research with Gossamer, Mannkind; and is a consultant for United Therapeutics. JA. Barber\u00e0 has received grants or contracts from Janssen-Cilag and Merck Sharp & Dome; consulting fees from Janssen, Cilag and Merck Sharp & Dome; honoraria from Janssen, Cilag, Merck Sharp & Dome, AOP Orphan, and Ferrer International; and support for attending meetings and\/or travel from Janssen, Cilag, Merck Sharp & Dome, AOP Orphan. D.G. Kiely has received grants or contracts from Janssen Pharmaceuticals, National Institute of Health Research Sheffield Biomedical Research Centre, Ferrer, and United Therapeutics; consulting fees from Janssen Pharmaceuticals, Ferrer, Altavant, MSD, United Therapeutics, Liquidia, Gossamer Bio, and Apollo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen Pharmaceuticals, Ferrer, Altavant, MSD, and United Therapeutics; support for attending meetings and\/or travel from Janssen, Ferrer, MSD, and United Therapeutics; and has participated on a safety monitoring board or advisory board for Janssen, MSD, and Liquidia. DGK is also leads the UK National Audit of Pulmonary Hypertension. D. Lee, B. Wu,, S. Hwang, S. Seaman, and M. Broderick are paid employees of United Therapeutics. J. Elwing consults for United Therapeutics, Gossamer Bio, Liquida, Merck, Janssen\/Actelion\/Johnson&Johnson, Insmed, and Pulmovant and has received research support from United Therapeutics, Gossamer Bio, Acceleron\/Merck, Pharmosa\/Liquidia, Lung LLC, Pulmovant. Inhibikase, Insmed, Novartis, and NS Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Trial protocols were approved by the institutional review board at each participating site. Trials were conducted in accordance with Good Clinical Practice guidelines, and all participants provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}